Unraveling the Possible Routes of SARS-COV-2 Invasion into the Central Nervous System

Abstract

Purpose of Review

To describe the possible neuroinvasion pathways of Severe Acute Respiratory Syndrome-related Coronavirus-2 (SARS-CoV-2), the virus responsible for the Coronavirus disease-19 (Covid-19) pandemic.

Recent Findings

We present data regarding the family of Coronaviruses (CoVs) and the central nervous system (CNS), and describe parallels between SARS-CoV-2 and other members of the family, which have been investigated in more depth and combine these findings with the recent advancements regarding SARS-CoV-2.

Summary

SARS-CoV-2 like other CoVs is neuroinvasive, neurotropic and neurovirulent. Two main pathways of CNS penetration seem to be the strongest candidates, the hematogenous and the neuronal. Τhe olfactory route in particular appears to play a significant role in neuroinvasion of coronaviruses and SARS-CoV-2, as well. However, existing data suggest that other routes, involving the nasal epithelium in general, lymphatic tissue and the CSF may also play roles in SARS-CoV-2 invasion into the CNS.

Introduction

Coronaviruses (CoVs) are a large family of viruses, capable of infecting many species of birds and mammals [1–3]. There are seven coronaviruses known to infect humans, called human coronaviruses (HCoVs) [4–6]. Clinically, infection with a coronavirus can be either asymptomatic or present with respiratory, gastrointestinal (GI), and neurological symptoms [7]. Four HCoVs, namely 229E, OC43, HKU1, NL63, are not considered to be very pathogenic [8, 9], while the rest, Severe Acute Respiratory Syndrome-related Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome-related Coronavirus (MERS-CoV) have caused two epidemics so far [8, 10–12], and the novel SARS-CoV-2 caused the current pandemic [13–16]; all these viral strands can lead to acute respiratory failure.

In this review, we aim to shed some light into how this novel virus can impact the central nervous system (CNS) by describing the routes of its invasion into the CNS.

Presence of coronaviruses in the CNS

Many studies have shown that coronaviruses are neuroinvasive, neurotropic, and neurovirulent in animals and humans [17–22]. In animals, the mouse hepatitis virus (MHV), a member of the coronavirus family, can infect microglia and astrocytes [23], as well as Koppler cells at choroid plexuses; a systemic model of infection with SARS-CoV showed that the virus reached the brain [24]. It has also been reported that human coronaviruses have the ability to infect primary cultures of human neural cells, fetal and adult astrocytes, adult microglia and adult oligodendrocytes [25–27]. [Fig. 1].

Fig. 1.

A normal neuron and a neuron and astrocytes as infected with coronavirus.

The detection of HCoVs in human CNS samples was described in the early 1980s, in autopsy tissues of patients with Multiple Sclerosis (MS) [28]. RNA from endemic prototype HCoV strains OC43 and 229E has also been detected in human brain samples [19], and can persist over time [29]. Neurological manifestations have also been described in the symptom constellation of the two previous epidemics of MERS- [30, 31] and SARS-CoV [32], where the virus was also detected in cerebrospinal fluid (CSF) [21, 32, 33]. More specifically, it was shown that SARS-CoV could induce cerebral edema and meningeal vasodilation [34], neuronal morphological changes in the cortex and hypothalamus [35], neuronal ischemic lesions and necrosis, glial hyperplasia [36] and demyelination, while its genome sequences (viral particles) have also been detected in brain samples of infected patients [34–41].

Consequently, it comes as no surprise that a SARS-CoV-2 infection may present with neurological manifestations and CNS symptoms at high rates [42, 43], such as headache, confusion [44] and sensory disturbances, namely anosmia and ageusia [42•]. Additionally, entities such as encephalitis [45], acute cerebrovascular diseases [42, 46], acute necrotizing encephalopathy (ANE) [47], as well as demyelination and neuropathy [22] have also been reported in the current pandemic. Furthermore, the presence of SARS-CoV-2 has been established in the CSF of patients with acute neurologic symptoms, like seizures [48, 49] or encephalitis [45], at times combined with MRI findings pertaining to the condition at hand [48•]. Post-mortem examination of SARS-CoV-2-infected patients revealed the presence of SARS-CoV-2 in endothelial cells and pericytes of brain capillaries [50•] and neurons [50, 51], further confirming the presence of SARS-CoV-2 in the CNS. It has also been postulated that the presence of the virus in areas of the medulla, and the cardiorespiratory center in particular, may be one of the likely causes of COVID-19’s respiratory failure [22, 52].

Routes of neuroinvasion

It was quickly established that SARS-CoV-2 binds to the receptor of the Angiotensin Converting Enzyme 2 (ACE2) with higher affinity than the other HCoVs, due to some structural differences in its “Receptor Binding Domain” of the S spike protein (S) [15, 53, 54]. Receptors of ACE2 exist in almost all human organs [55, 56], as well as in endothelial cells [52] and the CNS [55] [Fig. 2]. As such, it is highly likely that SARS-CoV-2, similarly to SARS-CoV [57, 58], makes use of these receptors in order to penetrate these tissues and trigger the perpetuation of immune responses [59] or finally invade the CNS, via the different pathways that we describe below.

Figure 2.

Entry of the virus into the host CNS-related cell and further spread. The single-stranded RNA (ssRNA) genome of Severe Acute Respiratory Syndrome-related Coronavirus-2 (SARS-CoV-2) encodes large polyproteins, which are proteolytically cleaved into 16 non-structural proteins (nsps). In addition, 9–12 ORFs are encoded through the transcription of a nested set of subgenomic RNAs. The virus forms spherical particles consisting of four structural proteins: the envelope glycoprotein spike (S), the envelope (E) and membrane (M) transmembrane glycoproteins incorporated in the virion, and the protein nucleocapsid (N). The surface protein of the virus binds to its receptors, such as ACE 2. Following the entry of the virus into the host cell (such as the neuron), and the release of the viral genome, the viral RNA is uncoated in the cytoplasm. Translation of the viral polymerase protein is followed by RNA replication and subgenomic transcription; ORF1a and ORF1ab are translated to create pp1a and pp1ab, which are cleaved by the proteases that are encoded by ORF1a to produce 16 nsps that form the RNA replicase–transcriptase complex. During the phase of replication, full-length (−)RNA copies of the genome are shaped and form templates for full-length (+)RNA genomes. Subgenomic (−)RNAs are transcribed into subgenomic (+)mRNAs. The step of translation is followed by the assembling of the resulting structural proteins into the nucleocapsid and viral envelope at the ER–Golgi intermediate compartment (ERGIC), followed by release of the nascent virion from the infected neuron cell. Created with a modified Biorender template (under license) as per de Wit et al. Nature Reviews Microbiology volume 14, pages523–534(2016).

The HEMATOGENOUS pathway

Viremia

Viremia follows the primary infection, and is the phase when most neurotropic viruses are present into the bloodstream, where they possibly stay for a period of time, before they finally reach the CNS [60]. Although HCoVs seem to mainly infect the respiratory tract and be self-restricting, they can potentially disrupt the epithelium barrier and invade the bloodstream [18]. Type II alveolar epithelial cells, which highly express ACE2, are the cells mainly infected by SARS-CoVs [39], thus allowing entrance of the virus to the blood circulation. Another possible pathway to the blood circulation could be through the epithelial cells of the GI tract [59], which also express ACE2 receptors and can be infected by SARS-CoV-2 [61–63]. While other pathways cannot be excluded, passage through the respiratory tract is the most plausible scenario.

Penetration through the Blood-brain- barrier

Once in the blood circulation, SARS-CoV-2 could bind to the ACE2 receptors of the endothelium [50, 52, 55] and disrupt the Blood Brain Barrier (BBB), inducing edema, intracranial hypertension and/or penetration of the virus in the CNS [64, 65]. Neuroinvasion has been described for other coronaviruses in the past [29, 66]. In greater detail, Cabirac et al. (1993) showed that intravenous (IV) inoculation with MHV in owl monkeys led to brain and spinal cord infection, with the presence of viral RNA and/or antigen in the brain sites of inflammation, the blood vessels, and the endothelium [67]. Additionally, MERS-CoV can access the bloodstream, subsequently infecting endothelial cells in vivo [68]. Finally, Paniz-Mondolfi et al., (2020) observed viral-like particles of SARS-CoV-2 in the endothelial cells and pericytes of brain capillaries as well as astrocytic processes, which actively overrode the BBB [50•], strongly supporting a hematogenous-endothelial neuroinvasion-based hypothesis for SARS-CoV-2.

In a similar way, it can be postulated that SARS-CoV-2 could also infect the endothelial cells of the blood-cerebrospinal fluid barrier (BCSFB), and then spread into the CNS. Moreover, the choroid plexus and the circumventricular cerebral organs are not protected by the BBB, and could thus be gates for the penetration of a virus into the CNS [69].

SARS-CoV-2 could also enter the CNS under conditions promoting an increase of the permeability of the BBB, as a result of the release of inflammatory mediators (chemokines, cytokines) [70], and even a cytokine storm, following inflammation or hypoxemia induced by the respiratory distress syndrome, or even psychological stress [59, 71–73]. This paracellular transmigration pathway is mainly mediated by the destabilization or disruption of the tight junctions of the BBB [69].

Peripheral immune cell transmigration - the “trojan horse” mechanism

SARS-CoV-2 could also infect bloodstream leukocytes (mainly monocytes/macrophages) [65] and myeloid cells, which become a viral pool for the diffusion of the virus towards the CNS [69, 74, 75]. SARS-CoV can infect lymphocytes and monocytes near the vessel wall [34, 35, 38] and seems to use this “Trojan Horse” mechanism [18, 76]. Other coronaviruses present similar abilities; MHV can infect macrophages [23], while HCoV-OC43 and HCoV-229E can infect human monocytes/macrophages [76, 77]. In addition, HCoV-229E was able to infect murine and human dendritic cells in vitro [78], which express the human aminopeptidase N (CD13) leading to their subsequent activation [79]. SARS-CoV is also speculated to have as a binding receptor, the human CD13 [80]. It has been shown to infect immune cells, monocytes, macrophages and T lymphocytes in particular, which are consistently reduced in these patients (lymphopenia), even at early disease stages [35], something that has been reported for SARS-CoV-2 patients as well [42•]. Thus, we can hypothesize that SARS-CoV-2 uses immune circulating cells [42•] and dendritic cells to disseminate into other tissues and the CNS. It is possible that monocytes/macrophages could also be a “future” source of SARS-CoV-2, as is the case of other HCoVs [19], since the infection of these leukocytic cell lines can persist over time [76].

The neuronal pathway

Another possible pathway for the penetration into the CNS for SARS-CoV-2 could be the neuronal pathway. Some viruses can invade from the nerve “ending”, i.e. the peripheral nerves [64, 81]. However, some viruses can invade from the nerve “ending”, i.e. the peripheral nerves [81], and by the mechanism of active transport within the neurons, more specifically through the motor proteins kinesin and dynein [69], and via microtubules, travel in a retrograde way and reach the CNS [82]. These neurons could be motor, sensory or autonomic neurons, but are most often olfactory neurons [69, 81, 83].

Τhere is growing evidence that CoVs may initially infect peripheral nerve endings and then enter the CNS through a synapse-connected route [84–86]. This trans-synaptic transmission has been well documented for some CoVs, such as HEV67 [84, 85, 87, 88]. There is also data supporting the notion that HCoV-OC43 might also penetrate the CNS through cranial peripheral nerves [40], as occurs with other respiratory viruses [respiratory syncytial virus (RSV) and influenza virus] [81]. Dubé et.al (2018) showed that viral particles could be passively released/diffused or transported via axonal transport (neuron-to-neuron) by axoplasmic flow in cell cultures [40]. It also appears that neurons are very sensitive to SARS-CoV infection, due to their host cell receptors [39]. More specifically, the S1 unit of the S protein of the virus binds to ACE2 receptor of the neuron and with the action of the serine protease transmembrane protease, serine 2 (TMPRSS2) activates the S protein, that allows the virus to invade the neuron [89].

The olfactory pathway

The olfactory pathway is an excellent neuronal pathway for neuroinvasive respiratory viruses [81] that access the body intranasally [64], as the olfactory nerve communicates both with the nasal epithelium and the olfactory bulb [64, 69]. This pathway seems to be one possible mechanism of neuroinvasion for coronaviruses, including SARS-CoV-2 [39, 90, 91].

In animal models, intranasal inhalation of CoVs can lead to cerebral infection. For example, MHV induced infection in mice, and its RNA was detected in brain and muscles [92]. HCoV-OC43 also invades the CNS via the neuroepithelium and starts neuropropagation at the olfactory bulbs [40, 92, 93]. It has been reported that 3 days after nasal inoculation in mice, viral antigens of HCoV-OC43 can be found in the olfactory bulb [both in the olfactory sensory neurons (OSN) and in dendrites-associated cilia [40]] while no virus is found in perivascular blood cells or other CNS sites [93]. The virus then has the ability to reach highly susceptible regions of the cortex, the mesolimbic cortex or other areas associated with olfaction [40], such as the hippocampus and the amygdala, and finally through trans-neuronal propagation, it may reach the brainstem and the spinal cord [94]. The virus can be detected in the entirety of the brain just 7 days after the nasal inoculation, suggesting a relatively rapid dissemination once it invades the CNS, leading to acute encephalitis and death [93]. Moreover, ablation of the olfactory bulb after nasal infection of MHV blocked the spread [95], strongly supporting the olfactory pathway dissemination theory. SARS-CoV, which is homologous to SARS-CoV-2, was also detected in the CNS of susceptible mice after intranasal infection, showing its neuroinvasive capabilities [39, 73]. More specifically, Netland et al. (2008) detected SARS-CoV in the olfactory bulb of mice approximately 3 days after nasal inhalation, and in the mesolimbic cortex only 1 day later, in addition to other brain regions and the brainstem, invading almost the entirety of the brain [39].

Other neuronal routes

SARS-CoV-2 might also be transferred to the CNS through the trigeminal nerve, which innervates nociceptive cells in the nasal cavity, and has been successfully tested for drug transportation [96, 97]. Sensory nerve endings of the trigeminal nerve also exist in the conjunctiva, where SARS-CoV-2 RNA fragments have been found in a patient with conjunctivitis [98], and in the taste buds, ascending not only in trigeminal nuclei, but also to the nuclei of the solitary tract [59].

It has been demonstrated that some viruses, such as influenza, can enter the CNS via the sensory fiber of the vagus nerve in the respiratory tract [81, 86, 99–101]. This also represents another communication route between the emesis center, the vagus nerve and the GI tract, which may play a role in this retrograde penetration of the SARS-CoV-2 to the CNS [59]. In addition, local peripheral nerves from the GI system might be infected, as SARS-CoV-2 also infects the GI tract [61–63]. As noted above, many researchers have demonstrated that the brain stem is an area that is particularly infected by SARS-CoV [39, 73] and MERS-CoV [91]; this adds support to the notion that through trans-synaptic transmission, SARS-CoV-2 might also infect the brainstem from the respiratory system [52]. However, no direct proof that SARS-CoV-2 and HCoVs use the vagus nerve for neuroinvasive purposes has been published [59].

The neurogenic hypothesis

It is worth mentioning that dyspnea may stem from the primary CNS infection, mainly through the olfactory mechanism that leads to the brainstem, where the stem nuclei and the solitary tract are connected to the respiratory system [52, 102]. Netland et al. (2008) demonstrated that the main gate of SARS-CoV infection in mice was the olfactory pathway and could lead to death. However, the presence of the virus in lungs was low suggesting that infected neurons in the medulla and the cardiorespiratory center were responsible for this outcome [39]. This scenario proposes that direct infection of the CNS might be the primary gate of the virus in the organism [39, 52]. Additionally, postmortem examination of SARS-CoV patients detected viral particles in the brain almost exclusively in neurons, rather than in glia [34–36], adding more support to the neuronal rather than the hematogenous pathway.

Lymphatic tissue and CSF

A recent study found that the genes for ACE2 receptors and TMPRSS2, responsible for the binding of SARS-CoV-2, are expressed in the olfactory epithelial support and stem cells, but not in the olfactory sensory neurons (OSN) of mice and humans [103]. It has also been demonstrated that nasal inoculation of HCoV-229E to human volunteers disrupted the nasal epithelium, damaging and decreasing the number of the ciliated cells [104]. Perineural spaces of olfactory nerves and the nasal lymphatic tissue are important for drainage of the CSF, as they communicate with the CSF through channels made by the ensheathing cells [105, 106]. That means that the nasal olfactory epithelium and its lymphatic tissue may contribute to SARS-CoV-2 neuroinvasion in another indirect pathway.

Lymphatic endothelial cells express receptors of CD209L, another receptor for SARS-CoVs, with lower affinity than ACE2 that is expressed mainly in lymphatic and liver tissues [107, 108]. It has been described that human hilar and mesenteric lymph nodes can be invaded by SARS-CoV [109, 110]. It is not unreasonable to hypothesize that other lymphatic networks, like those in oral tissues [111] or in the ocular mucosa [112] could be targets for SARS-CoV-2. Following this train of thought, the case of a patient presenting with seizures and SARS-CoV-2 in the CSF, 10 days after conjunctivitis [49], demonstrates possible neuroinvasion through the conjunctiva. According to this theory, viremia could be the sequela of infection of lymphatic tissue in the affected organ, such as the respiratory or GI tract [18, 59], leading to the neuroinvasion via the aforementioned hematogenous route.

The CNS microenvironment following SARS-CoV-2 infection is presented at Fig. 3 [Fig. 3].

Fig. 3.

The CNS microenvironment following SARS-CoV-2 infection. Spread of SARS-CoV-2 from lungs to the CNS can most likely be achieved through the haematogenous route. In addition, it can enter the CNS through the olfactory bulb, and once the infectious agent persists due to the inability of the immune system to control/suppress viral replication, the virus may reach the whole brain and the CSF, and participate in demyelination. In the hematogenous route, SARS-CoV-2 may gain access by infecting endothelial cells of the blood-brain-barrier, epithelial cells of the blood-cerebrospinal fluid barrier in the choroid plexus, or it may indeed use inflammatory cells as “Trojan horse” to obtain access into the CNS. Experimental data suggest that primary glial cultures can secrete a series of inflammatory cytokines participating in the perpetuation of viral infection and further inflicting CNS tissue damage. The role of astrocytes in the machinery of SARS-CoV-2 mediated CNS pathology is yet undetermined and remains to be defined.

Conclusions

In an attempt to understand the possible mechanisms of SARS-CoV-2 neuroinvasion, it is reasonable to study the neuroinvasive behavior of known CoVs that have been studied for a longer period of time. The two basic common pathways for viral neuroinvasion that have been better described so far are hematogenous and neuronal. It has been demonstrated that coronaviruses can use either pathway to achieve CNS penetration. SARS-CoV-2 seems to not be an exception, as it shares common features with the other coronaviruses and can induce neurological symptoms. There are indications that SARS-CoV-2 can take advantage of both the hematogenous and neuronal routes, as it principally uses the ACE2 receptor that exists in circulatory and nervous systems. In addition, SARS-CoV-2 may also penetrate lymphatic tissues leading to entrance to the CNS.

Based on the data presented in this review, the CNS may be affected by a subsequent effect of a primary systemic infection, through hematogenous or neuronal pathways. However, the CNS may also be the primary entry organ, infected mainly through the olfactory route, via which the virus enters the boby and spreads to other systems. In that case, the aforementioned “neurogenic hypothesis” is reinforced, and this invasion route could be particularly dangerous, as it could lead to the infection of the brainstem and the respiratory center, causing respiratory failure. More research is needed to confirm these hypotheses and will lead to more efficient therapeutic and preventive strategies.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.